Table 2 Baseline parameters and efficacy outcomes in placebo groups from paliperidone ER and risperidone studies
From: Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
Baseline Demographic and Clinical Characteristics | Placebo (PALI) n = 95 | Placebo (RIS) n = 122 | p Value |
|---|---|---|---|
Age, years, mean (SD) | 36.7 (10.9) | 38.0 (10.1) | 0.338 |
Female, n (%) | 23 (24.2) | 18 (14.8) | 0.083 |
Race, n (%) | |||
Caucasian | 65 (91.6) | 73 (93.6) | 0.758 |
Other | 6 (8.5) | 5 (6.4) | |
BMI, mean (SD), kg/m2 | 24.9 (5.2) | 25.3 (3.2) | 0.538 |
PANSS total score, mean (SD) | 94.5 (12.2) | 92.6 (12.3) | 0.254 |
CGI-S, score (SD) | 4.6 (0.7) | 4.7 (0.8) | 0.105 |
PANSS, Adjusted Mean Change (SE) at End Point | Placebo (PALI) n = 92 | Placebo (RIS) n = 94 | p Value |
Total score | -6.5 (2.5) | -5.4 (2.5) | 0.768 |
Factor score | |||
Negative | -1.3 (0.7) | -2.3 (0.7) | 0.280 |
Positive | -2.5 (0.8) | -1.6 (0.8) | 0.423 |
Anxiety/depression | -1.3 (0.4) | -1.8 (0.4) | 0.402 |
Disorganized thoughts | -1.2 (0.6) | -0.6 (0.6) | 0.507 |
Uncontrolled hostility/excitement | 0.4 (0.5) | 0.9 (0.5) | 0.530 |